J & D Pharmaceuticals LLC
J & D Pharmaceuticals is dedicated to discovering, developing, and delivering safe and effective treatments for serious diseases, particularly focusing on traumatic brain injury, burns, and operative pain. Their innovative approach combines salicylic acid with liposomal technology to enhance drug delivery and efficacy, aiming to improve patient outcomes while minimizing side effects.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Salicylate-based liposomal systemic formulations
Liposomal formulations of salicylate-class active moieties developed for systemic use (intravenous and oral) intended to provide analgesic and anti-inflammatory activity with improved gastrointestinal safety.
Salicylate-based topical liposomal formulations
Topical liposomal formulations (cream, lotion, powder) intended to provide local analgesia and promote wound healing for burns and other skin injuries.
Salicylate-based liposomal systemic formulations
Liposomal formulations of salicylate-class active moieties developed for systemic use (intravenous and oral) intended to provide analgesic and anti-inflammatory activity with improved gastrointestinal safety.
Salicylate-based topical liposomal formulations
Topical liposomal formulations (cream, lotion, powder) intended to provide local analgesia and promote wound healing for burns and other skin injuries.
Services
In-house development of liposomal suspensions and multiple formulation types for parenteral, oral, and topical delivery of salicylate-class active moieties.
Design and execution of in vivo efficacy studies and mechanistic investigations in rodent models for indications such as traumatic brain injury, progeroid syndromes, and polycystic kidney disease.
Preparation and submission activities to obtain orphan drug and rare pediatric disease designations and associated regulatory interactions.
In-house development of liposomal suspensions and multiple formulation types for parenteral, oral, and topical delivery of salicylate-class active moieties.
Design and execution of in vivo efficacy studies and mechanistic investigations in rodent models for indications such as traumatic brain injury, progeroid syndromes, and polycystic kidney disease.
Preparation and submission activities to obtain orphan drug and rare pediatric disease designations and associated regulatory interactions.
Expertise Areas
- Liposomal drug delivery
- Formulation development for multiple administration routes
- Preclinical translational pharmacology
- Early-phase clinical development and safety assessment
Key Technologies
- Liposomal formulations
- Phosphatidylcholine-associated drug pre-association
- Lyophilization (freeze-drying)
- Parenteral formulation methods (IV/IM/SC)
News & Updates
J & D Pharmaceuticals received FDA orphan drug designation for JD-004 and JD-005 for the treatment of Progeria and related conditions.
J & D Pharmaceuticals received FDA orphan drug designation for JD-004 and JD-005 for the treatment of Progeria and related conditions.